During pregnancy, the demand for iron is markedly increased due to the expansion of the pregnant woman’s hemoglobin mass and ...

The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.